

Paolo Angeli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3311590/publications.pdf>

Version: 2024-02-01

179
papers

20,316
citations

16451

64
h-index

10734

138
g-index

185
all docs

185
docs citations

185
times ranked

10230
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	1.3	2,211
2	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 406-460.	3.7	1,762
3	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.	7.3	744
4	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
5	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
6	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
7	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
8	Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. <i>Gastroenterology</i> , 1996, 111, 1002-1010.	1.3	528
9	Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. <i>Hepatology</i> , 1999, 29, 1690-1697.	7.3	526
10	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	7.3	493
11	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <i>Journal of Hepatology</i> , 2015, 63, 1272-1284.	3.7	463
12	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
13	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542.	7.3	349
14	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
15	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
16	Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the β - blocker alone. <i>Hepatology</i> , 1997, 26, 34-39.	7.3	294
17	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
18	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i> , 2015, 62, 567-574.	7.3	283

#	ARTICLE	IF	CITATIONS
19	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
20	News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. <i>Journal of Hepatology</i> , 2019, 71, 811-822.	3.7	272
21	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281.	3.7	259
22	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	3.7	243
23	Malnutrition in alcoholic and virus-related cirrhosis. <i>American Journal of Clinical Nutrition</i> , 1996, 63, 602-609.	4.7	242
24	Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2013, 59, 482-489.	3.7	232
25	Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. <i>Hepatology</i> , 1999, 29, 1662-1667.	7.3	230
26	Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. <i>Hepatology</i> , 2016, 63, 983-992.	7.3	225
27	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
28	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
29	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 670-685.	3.7	204
30	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	12.1	190
31	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. <i>Hepatology</i> , 2016, 63, 1299-1309.	7.3	186
32	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
33	Detection of minimal hepatic encephalopathy: Normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. <i>Journal of Hepatology</i> , 2008, 49, 346-353.	3.7	175
34	Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 23.	30.5	172
35	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
36	How to improve care in outpatients with cirrhosis and ascites: A new model of care coordination by consultant hepatologists. <i>Journal of Hepatology</i> , 2013, 59, 257-264.	3.7	146

#	ARTICLE	IF	CITATIONS
37	The animal naming test: An easy tool for the assessment of hepatic encephalopathy. <i>Hepatology</i> , 2017, 66, 198-208.	7.3	135
38	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
39	Acute effects of the oral administration of midodrine, an α -adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. <i>Hepatology</i> , 1998, 28, 937-943.	7.3	131
40	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	8.1	131
41	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. <i>Journal of Hepatology</i> , 2018, 69, 345-352.	3.7	128
42	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	4.4	127
43	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 438-445.e5.	4.4	125
44	Cirrhosis and muscle cramps: Evidence of a causal relationship. <i>Hepatology</i> , 1996, 23, 264-273.	7.3	124
45	Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. <i>Gut</i> , 2010, 59, 98-104.	12.1	122
46	Infections complicating cirrhosis. <i>Liver International</i> , 2018, 38, 126-133.	3.9	122
47	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 57-65.	3.7	112
48	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017, 49, 121-137.	0.9	111
49	Statins: Old drugs as new therapy for liver diseases?. <i>Journal of Hepatology</i> , 2019, 70, 194-202.	3.7	108
50	Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. <i>Hepatology</i> , 2013, 57, 266-276.	7.3	104
51	Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 1177-1184.	3.7	101
52	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography. <i>Hepatology</i> , 1993, 17, 219-224.	7.3	100
53	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. <i>Hepatology</i> , 1994, 19, 72-79.	7.3	100
54	Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. <i>Liver International</i> , 2019, 39, 98-105.	3.9	100

#	ARTICLE	IF	CITATIONS
55	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. <i>Gut</i> , 2018, 67, 1892-1899.	12.1	98
56	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
57	Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, S93-S103.	3.7	94
58	Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. <i>Journal of Hepatology</i> , 2012, 57, 1135-1140.	3.7	87
59	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622.	12.1	86
60	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. <i>Hepatology</i> , 1991, 14, 231-236.	7.3	85
61	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
62	Efficacy of Albumin Treatment for Patients with Cirrhosisâ€andâ€Infections Unrelated to Spontaneous Bacterialâ€Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	4.4	77
63	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
64	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
65	Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 75-84.	3.7	70
66	Towards a new definition of decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 202-207.	3.7	66
67	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. <i>Hepatology</i> , 1995, 22, 915-920.	7.3	65
68	Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the <sc>I</sc>nternational <sc>C</sc>lub of <sc>A</sc>scites. <i>Liver International</i> , 2013, 33, 16-23.	3.9	63
69	Management of ascites and hepatorenal syndrome. <i>Hepatology International</i> , 2018, 12, 122-134.	4.2	62
70	The impact of infection by multidrugâ€resistant agents in patients with cirrhosis. A multicenter prospective study. <i>Liver International</i> , 2017, 37, 71-79.	3.9	57
71	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. <i>Hepatology</i> , 2021, 73, 1909-1919.	7.3	53
72	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. <i>World Journal of Gastroenterology</i> , 2014, 20, 15756.	3.3	50

#	ARTICLE	IF	CITATIONS
73	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	3.7	45
74	Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysine-vasopressin administration in alcoholic cirrhosis. <i>Digestive Diseases and Sciences</i> , 1988, 33, 1103-1109.	2.3	43
75	Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G298-G304.	3.4	42
76	Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	41
77	Cardiovascular predictors of death in patients with cirrhosis. <i>Hepatology</i> , 2018, 68, 215-223.	7.3	41
78	Abnormalities in the 24-hour rhythm of skin temperature in cirrhosis: Sleep-wake and general clinical implications. <i>Liver International</i> , 2017, 37, 1833-1842.	3.9	39
79	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1188-1196.e3.	4.4	39
80	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
81	Q-T Interval Prolongation in Liver Cirrhosis. Reversibility after Orthotopic Liver Transplantation.. <i>International Heart Journal</i> , 1998, 39, 321-329.	0.6	37
82	Renal Function in Cirrhosis: A Critical Review of Available Tools. <i>Seminars in Liver Disease</i> , 2018, 38, 230-241.	3.6	37
83	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	2.0	37
84	Sepsis-induced acute kidney injury in patients with cirrhosis. <i>Hepatology International</i> , 2016, 10, 115-123.	4.2	36
85	New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S14-S26.	3.7	36
86	The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. <i>Liver International</i> , 2005, 25, 429-437.	3.9	35
87	Why and how to measure renal function in patients with liver disease. <i>Liver International</i> , 2017, 37, 116-122.	3.9	35
88	New diagnostic criteria and management of acute kidney injury. <i>Journal of Hepatology</i> , 2017, 66, 860-861.	3.7	35
89	New ICA criteria for the diagnosis of acute kidney injury in cirrhotic patients: can we use an imputed value of serum creatinine?. <i>Liver International</i> , 2015, 35, 2108-2114.	3.9	33
90	Natural history of acute kidney disease in patients with cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 578-583.	3.7	32

#	ARTICLE	IF	CITATIONS
91	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. <i>American Journal of Medicine</i> , 2017, 130, 372-375.	1.5	31
92	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	3.7	31
93	Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. <i>Hepatology</i> , 1995, 22, 808-813.	7.3	30
94	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. <i>Gut</i> , 2021, 70, 1914-1924.	12.1	30
95	A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. <i>Hepatology</i> , 2016, 63, 1651-1659.	7.3	29
96	Changes in the epidemiology and management of bacterial infections in cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 437-445.	8.9	29
97	Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. <i>American Journal of Gastroenterology</i> , 2017, 112, 1575-1583.	0.4	28
98	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. <i>Hepatology</i> , 1994, 19, 72-9.	7.3	27
99	Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications. <i>Hepatology</i> , 1992, 16, 1389-1394.	7.3	26
100	Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. <i>Hepatology</i> , 1992, 15, 651-654.	7.3	23
101	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3134.	2.4	19
102	Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. <i>Hepatology</i> , 2000, 31, 304-310.	7.3	18
103	Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation. <i>Hepatology</i> , 2016, 64, 923-930.	7.3	18
104	Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 626-632.	1.6	18
105	Prognosis of hepatorenal syndrome " has it changed with current practice?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 44-46.	3.7	17
106	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	4.9	17
107	Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 358-366.e8.	4.4	16
108	Location and allocation: Inequity of access to liver transplantation for patients with severe acute-on-chronic liver failure in Europe. <i>Liver Transplantation</i> , 2022, 28, 1429-1440.	2.4	16

#	ARTICLE	IF	CITATIONS
109	Neuropsychiatric performance in patients with cirrhosis: Who is "normal"? Journal of Hepatology, 2017, 66, 825-835.	3.7	15
110	Changes in Accident & Emergency Visits and Return Visits in Relation to the Enforcement of Daylight Saving Time and Photoperiod. Journal of Biological Rhythms, 2018, 33, 555-564.	2.6	15
111	Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Reports, 2021, 3, 100355.	4.9	15
112	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Digestive and Liver Disease, 2016, 48, 197-202.	0.9	14
113	Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Medicine: Evidence and Research, 2010, 2, 87.	2.5	13
114	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. Journal of Hepatology, 2019, 70, 648-657.	3.7	13
115	AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfusion, 2016, 14, 8-22.	0.4	13
116	Covert Hepatic Encephalopathy: Does the Mini-Mental State Examination Help?. Journal of Clinical and Experimental Hepatology, 2014, 4, 89-93.	0.9	12
117	Occult liver disease burden: Analysis from a large general practitioners'™ database. United European Gastroenterology Journal, 2017, 5, 982-986.	3.8	12
118	Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations. Digestive and Liver Disease, 2021, 53, 1468-1475.	0.9	12
119	Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification. Clinical and Experimental Hepatology, 2021, 7, 270-277.	1.3	12
120	Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Archives of Internal Medicine, 1991, 151, 678-82.	3.8	12
121	Effect of Morning Light Glasses and Night Short-Wavelength Filter Glasses on Sleep-Wake Rhythmicity in Medical Inpatients. Frontiers in Physiology, 2020, 11, 5.	2.8	10
122	Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation?. Clinics in Liver Disease, 2021, 25, 357-372.	2.1	10
123	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2021, 53, 1089-1104.	0.9	10
124	Managing complications in cirrhotic patients. United European Gastroenterology Journal, 2015, 3, 80-94.	3.8	9
125	Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1419-1431.	2.3	9
126	Liver Fibrosis and Steatosis in Alstr�m Syndrome: A Genetic Model for Metabolic Syndrome. Diagnostics, 2021, 11, 797.	2.6	9

#	ARTICLE	IF	CITATIONS
127	Acute-on-Chronic Liver Failure in Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4406.	2.4	9
128	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. <i>Hepatology</i> , 1991, 14, 231-236.	7.3	9
129	Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000050.	2.7	8
130	Lack of consensus for usage of β -blockers in end-stage liver disease. <i>Gut</i> , 2016, 65, 1058-1060.	12.1	8
131	Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine. <i>Metabolic Brain Disease</i> , 2016, 31, 965-974.	2.9	8
132	Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2019, 34, 1803-1812.	2.9	8
133	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. <i>International Journal of Cardiology</i> , 2021, 339, 219-224.	1.7	8
134	Early markers of neural dysfunction and compensation: A model from minimal hepatic encephalopathy. <i>Clinical Neurophysiology</i> , 2014, 125, 1138-1144.	1.5	6
135	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. <i>Scientific Reports</i> , 2019, 9, 20126.	3.3	6
136	Fam20C-mediated phosphorylation of osteopontin is critical for its secretion but dispensable for its action as a cytokine in the activation of hepatic stellate cells in liver fibrogenesis. <i>FASEB Journal</i> , 2020, 34, 1122-1135.	0.5	6
137	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , 2019, 70, e53.	3.7	5
138	Current Concepts on Bacterial and Fungal Infections in Cirrhosis. <i>Clinical Liver Disease</i> , 2019, 14, 87-91.	2.1	5
139	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	2.4	5
140	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. <i>Hepatology</i> , 1994, 19, 72-79.	7.3	5
141	Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. <i>Minerva Gastroenterologica E Dietologica</i> , 2008, 54, 259-75.	2.2	5
142	Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 273-275.	0.9	4
143	Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI" To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 744-746.	3.7	4
144	Reply. <i>Hepatology</i> , 2016, 64, 998-999.	7.3	4

#	ARTICLE	IF	CITATIONS
145	Introducing the Expert Opinion series. <i>Journal of Hepatology</i> , 2020, 73, 5.	3.7	4
146	Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in advanced chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e656-e661.	1.6	4
147	AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update. <i>Blood Transfusion</i> , 2021, 19, 9-13.	0.4	4
148	Acute-on-Chronic Liver Failure: From Basic Research to Clinical Applications. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-3.	1.9	3
149	The influence of HEhistory, HEstatus and neuropsychological test type on learning ability in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 861-870.	3.9	3
150	ERP correlates of cognitive control and food-related processing in normal weight and severely obese candidates for bariatric surgery: Data gathered using a newly designed Simon task. <i>Biological Psychology</i> , 2020, 149, 107804.	2.2	3
151	Endoscopic diode laser therapy for gastric hyperplastic polyps in cirrhotic patients. <i>Lasers in Medical Science</i> , 2021, 36, 975-979.	2.1	3
152	Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?. <i>Liver Transplantation</i> , 2015, 21, 1335-1337.	2.4	2
153	Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?". <i>Journal of Hepatology</i> , 2019, 70, 1028-1030.	3.7	2
154	Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. <i>Digestive and Liver Disease</i> , 2020, 52, 235-236.	0.9	2
155	Reply to: "Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis". <i>Journal of Hepatology</i> , 2020, 72, 582-583.	3.7	2
156	Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. <i>GastroHep</i> , 2022, 2022, 1-8.	0.6	2
157	Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 241-248.	0.8	1
158	Reply to: "To close the stable door before the horse has bolted". <i>Journal of Hepatology</i> , 2014, 60, 680-681.	3.7	1
159	Reply. <i>Hepatology</i> , 2016, 64, 318-318.	7.3	1
160	Brexit from current guideline recommendations?. <i>Gut</i> , 2016, 65, 1919.1-1919.	12.1	1
161	The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great country. <i>Hepatology International</i> , 2019, 13, 395-398.	4.2	1
162	Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. <i>Liver Transplantation</i> , 2019, 25, 362-364.	2.4	1

#	ARTICLE	IF	CITATIONS
163	A step forward in the choice of fluid for early resuscitation of critically ill patients with cirrhosis. <i>Hepatology International</i> , 2021, 15, 858-859.	4.2	1
164	Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021, 75, 1010-1012.	3.7	1
165	Combined Pharmacological and Endoscopic Treatment for Worsening Gastroesophageal Varices in Patients with Cirrhosis. <i>Clinical and Experimental Gastroenterology</i> , 2022, Volume 15, 59-65.	2.3	1
166	Current management of uncomplicated ascites. <i>Clinical Liver Disease</i> , 2013, 2, 125-127.	2.1	0
167	Reply to: "Coordinated care models in cirrhosis; the need for further randomized controlled trials". <i>Journal of Hepatology</i> , 2014, 60, 466-467.	3.7	0
168	Reply. <i>Hepatology</i> , 2016, 64, 2268-2269.	7.3	0
169	Reply. <i>Hepatology</i> , 2016, 64, 2260-2262.	7.3	0
170	Reply to: "Tools and tactics for improving diagnosis of hepatic encephalopathy". <i>Journal of Hepatology</i> , 2017, 66, 1328-1329.	3.7	0
171	Liver Replantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 736-739.	0.6	0
172	Screening studies of transient elastography and FibroTest in the general population " Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246-247.	8.1	0
173	The reasons for my application. <i>Journal of Hepatology</i> , 2020, 72, 5-7.	3.7	0
174	The first year of the new editorial team. <i>Journal of Hepatology</i> , 2021, 74, 5-7.	3.7	0
175	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1510-1511.	4.4	0
176	Why have we performed a randomized controlled trial on our own dissemination policy?. <i>Journal of Hepatology</i> , 2021, 75, 261.	3.7	0
177	REPLY:. <i>Hepatology</i> , 2021, 74, 2324-2325.	7.3	0
178	Expectancy to Eat Modulates Cognitive Control and Attention Toward Irrelevant Food and Non-food Images in Healthy Starving Individuals. A Behavioral Study. <i>Frontiers in Psychology</i> , 2020, 11, 569867.	2.1	0
179	EASL International Recognition Awardee 2022: Dr. Pere Gin�s. <i>Journal of Hepatology</i> , 2022, , .	3.7	0